ATE470441T1 - Modulator der menschlichen mastzellaktivierung - Google Patents

Modulator der menschlichen mastzellaktivierung

Info

Publication number
ATE470441T1
ATE470441T1 AT98917959T AT98917959T ATE470441T1 AT E470441 T1 ATE470441 T1 AT E470441T1 AT 98917959 T AT98917959 T AT 98917959T AT 98917959 T AT98917959 T AT 98917959T AT E470441 T1 ATE470441 T1 AT E470441T1
Authority
AT
Austria
Prior art keywords
mast cell
purinoceptors
cell activation
modulator
atp binding
Prior art date
Application number
AT98917959T
Other languages
German (de)
English (en)
Inventor
Amir Pelleg
Edward Schulman
Original Assignee
Duska Scient Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scient Co filed Critical Duska Scient Co
Application granted granted Critical
Publication of ATE470441T1 publication Critical patent/ATE470441T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
AT98917959T 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung ATE470441T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (1)

Publication Number Publication Date
ATE470441T1 true ATE470441T1 (de) 2010-06-15

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917959T ATE470441T1 (de) 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung

Country Status (9)

Country Link
US (2) US6372724B1 (enExample)
EP (1) EP1011686B9 (enExample)
JP (1) JP2001518118A (enExample)
AT (1) ATE470441T1 (enExample)
AU (1) AU741713B2 (enExample)
CA (1) CA2288821C (enExample)
DE (1) DE69841711D1 (enExample)
DK (1) DK1011686T3 (enExample)
WO (1) WO1998042353A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470441T1 (de) * 1997-03-25 2010-06-15 Duska Scient Co Modulator der menschlichen mastzellaktivierung
DK1187617T3 (da) * 1999-06-18 2004-04-13 Alcon Mfg Ltd Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
GB9916757D0 (en) * 1999-07-17 1999-09-15 Glaxo Group Ltd Method
US20030166568A1 (en) * 2000-03-23 2003-09-04 Franz Kricek Organic compounds
JP2004520346A (ja) * 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ受容体発現のインデューサーとしてのアリールピペリジン誘導体
US20040147557A1 (en) * 2001-01-15 2004-07-29 Anne Bouillot Aryl piperidine derivatives as inducers of ldl-receptor expression
EP1351936A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
WO2003070902A2 (en) * 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
WO2004015396A2 (en) * 2002-08-13 2004-02-19 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
WO2004033636A2 (en) * 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
US20070009886A1 (en) * 2002-11-12 2007-01-11 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
AU2003302234A1 (en) * 2002-11-26 2004-06-18 Incyte Corporation Immune response associated proteins
US7829682B1 (en) 2003-04-30 2010-11-09 Incyte Corporation Human β-adrenergic receptor kinase nucleic acid molecule
US20060029548A1 (en) * 2004-07-22 2006-02-09 Amir Pelleg Methods of diagnosing, monitoring and treating pulmonary diseases
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
JP2010535013A (ja) * 2007-03-14 2010-11-18 シエラ モレキュラー コーポレイション 細胞および／または高分子の保存および／または安定化のための組成物、システムおよび方法
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
WO1995033048A2 (en) * 1994-05-27 1995-12-07 Glaxo Group Limited P2x receptors (purinoceptor family)
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
ATE470441T1 (de) * 1997-03-25 2010-06-15 Duska Scient Co Modulator der menschlichen mastzellaktivierung

Also Published As

Publication number Publication date
JP2001518118A (ja) 2001-10-09
EP1011686B9 (en) 2011-02-09
US6465441B2 (en) 2002-10-15
WO1998042353A1 (en) 1998-10-01
EP1011686B1 (en) 2010-06-09
US20020055515A1 (en) 2002-05-09
US6372724B1 (en) 2002-04-16
CA2288821A1 (en) 1998-10-01
EP1011686A4 (en) 2003-03-19
CA2288821C (en) 2008-10-14
AU741713B2 (en) 2001-12-06
DK1011686T3 (da) 2010-10-11
EP1011686A1 (en) 2000-06-28
DE69841711D1 (de) 2010-07-22
AU7098598A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
DE69841711D1 (de) Modulator der menschlichen mastzellaktivierung
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
DE69620458D1 (de) Benzofuran-carboxamide und -sulfonamide
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
PL367287A1 (en) Use of proteasome inhibitors to treat dry eye disorders
NO20052267L (no) Forbindelser, Preparater og Metoder
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
ES2039578T3 (es) Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
WO2004053144A3 (en) Modulation of stem cell differentiation by modulation of caspase-3 activity
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
WO2003049683A3 (en) Use of parapox b2l protein to treat cancer and modify immune responses
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
NO993546D0 (no) 1,4-dihydropyridinderivater og deres anvendelse i terapi
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use